NAV

Sodium phosphate, dibasic, unspecified form

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Sodium phosphate, dibasic, unspecified form is an osmotic laxative used to cleanse the colon before a colonoscopy.

Brand Names
Bss Ophthalmic Solution, Fleet Mineral Oil, Intersol, Isolyte S, Isoplate, Rejuvesol
Generic Name
Sodium phosphate, dibasic, unspecified form
DrugBank Accession Number
DB14504
Background

Not Available

Type
Small Molecule
Groups
Approved, Experimental
Synonyms
  • Sodium phosphate, dibasic, unspecified
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcetazolamideThe risk or severity of dehydration can be increased when Acetazolamide is combined with Sodium phosphate, dibasic, unspecified form.
AclidiniumThe therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Aclidinium.
AlfentanilThe therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Alfentanil.
AlloinThe risk or severity of adverse effects can be increased when Sodium phosphate, dibasic, unspecified form is combined with Alloin.
AlmasilateThe therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Almasilate.
Food Interactions
  • Take with a full glass of water.
  • Take with food.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Active Moieties
NameKindUNIICASInChI Key
Phosphoric acidunknownE4GA8884NN7664-38-2NBIIXXVUZAFLBC-UHFFFAOYSA-N
Phosphate ionionicNK08V8K8HR14265-44-2NBIIXXVUZAFLBC-UHFFFAOYSA-K
Sodium cationionicLYR4M0NH3717341-25-2FKNQFGJONOIPTF-UHFFFAOYSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
AminosynSodium phosphate, dibasic, unspecified form (425 mg/100mL) + Alanine (900 mg/100mL) + Arginine (690 mg/100mL) + Glycine (900 mg/100mL) + Histidine (210 mg/100mL) + Isoleucine (510 mg/100mL) + Leucine (660 mg/100mL) + Lysine acetate (510 mg/100mL) + Magnesium chloride hexahydrate (102 mg/100mL) + Methionine (280 mg/100mL) + Phenylalanine (310 mg/100mL) + Potassium chloride (487 mg/100mL) + Proline (610 mg/100mL) + Serine (300 mg/100mL) + Sodium chloride (28 mg/100mL) + Threonine (370 mg/100mL) + Tryptophan (120 mg/100mL) + Tyrosine (44 mg/100mL) + Valine (560 mg/100mL)Injection, solutionIntravenousHospira, Inc.2004-04-012010-08-01US flag
AminosynSodium phosphate, dibasic, unspecified form (425 mg/100mL) + Alanine (1100 mg/100mL) + Arginine (850 mg/100mL) + Glycine (1100 mg/100mL) + Histidine (260 mg/100mL) + Isoleucine (620 mg/100mL) + Leucine (810 mg/100mL) + Lysine acetate (624 mg/100mL) + Magnesium chloride hexahydrate (102 mg/100mL) + Methionine (340 mg/100mL) + Phenylalanine (380 mg/100mL) + Potassium chloride (487 mg/100mL) + Proline (750 mg/100mL) + Serine (370 mg/100mL) + Sodium chloride (28 mg/100mL) + Threonine (460 mg/100mL) + Tryptophan (150 mg/100mL) + Tyrosine (44 mg/100mL) + Valine (680 mg/100mL)Injection, solutionIntravenousHospira, Inc.2004-11-012015-04-01US flag
Aminosyn II in DextroseSodium phosphate, dibasic, unspecified form (49.3 mg/100mL) + Alanine (348 mg/100mL) + Arginine (356 mg/100mL) + Aspartic acid (245 mg/100mL) + D-glucose monohydrate (5 g/100mL) + Glutamic acid (258 mg/100mL) + Glycine (175 mg/100mL) + Histidine (105 mg/100mL) + Isoleucine (231 mg/100mL) + Leucine (350 mg/100mL) + Lysine acetate (368 mg/100mL) + Magnesium chloride hexahydrate (30 mg/100mL) + Methionine (60 mg/100mL) + N-acetyltyrosine (94 mg/100mL) + Phenylalanine (104 mg/100mL) + Potassium chloride (97 mg/100mL) + Proline (252 mg/100mL) + Serine (186 mg/100mL) + Sodium chloride (120 mg/100mL) + Threonine (140 mg/100mL) + Tryptophan (70 mg/100mL) + Valine (175 mg/100mL)Injection, solutionIntravenousHospira, Inc.1988-11-012010-01-01US flag
Aminosyn II with ElectrolytesSodium phosphate, dibasic, unspecified form (425 mg/100mL) + Alanine (844 mg/100mL) + Arginine (865 mg/100mL) + Aspartic acid (595 mg/100mL) + Glutamic acid (627 mg/100mL) + Glycine (425 mg/100mL) + Histidine (255 mg/100mL) + Isoleucine (561 mg/100mL) + Leucine (850 mg/100mL) + Lysine acetate (893 mg/100mL) + Magnesium chloride hexahydrate (102 mg/100mL) + Methionine (146 mg/100mL) + N-acetyltyrosine (230 mg/100mL) + Phenylalanine (253 mg/100mL) + Potassium chloride (492 mg/100mL) + Proline (614 mg/100mL) + Serine (450 mg/100mL) + Sodium chloride (60 mg/100mL) + Threonine (340 mg/100mL) + Tryptophan (170 mg/100mL) + Valine (425 mg/100mL)Injection, solutionIntravenousHospira, Inc.1986-04-032017-09-01US flag
BSS PLUSSodium phosphate, dibasic, unspecified form (0.433 mg) + Sodium phosphate, dibasic, unspecified form (0.42 mg) + Calcium chloride dihydrate (0.154 mg) + Dextrose, unspecified form (0.92 mg) + Glutathione disulfide (0.184 mg) + Magnesium chloride hexahydrate (0.2 mg) + Potassium chloride (0.395 mg) + Sodium bicarbonate (2.1 mg) + Sodium chloride (7.14 mg)LiquidOphthalmicบริษัท อัลคอน แลบอราทอรีส์ (ประเทศไทย) จำกัด1999-07-20Not applicableThailand flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
GR686LBA74
CAS number
10140-65-5

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
4CompletedOtherSickle Cell Disease (SCD)1
4WithdrawnBasic ScienceHeart Defects,Congenital1
3Unknown StatusTreatmentMalnutrition1
2Active Not RecruitingTreatmentAcute Malnutrition, Severe Acute Malnutrition / Sickle Cell Anemia1
1CompletedNot AvailableHealthy Subjects (HS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntravenous
Concentrate; kit; solutionOphthalmic
LiquidOphthalmic
LiquidRectal
SolutionIntravenous
LiquidOral
TabletOral
SolutionExtracorporeal
EnemaRectal
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at July 11, 2018 21:12 / Updated at June 12, 2020 16:53